Indeed, they enhance tumorigenicity in non-small cell lung cancer (NSCLC) and hepatocarcinoma cells (HCC) by targeting PTEN and TIMP3 tumor suppressors; in turn, they are activated by c-MET through the AP-1 transcription complex (Garofalo et al., 2009). This evidence concerns the gene MET and non-small cell lung carcinoma.